Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.84 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL14472019 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL899410 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2817795 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3013 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL25969 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3014 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL5598406 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6317379 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL27522597 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2175991 | 0.97 | HMGCR (0.98) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011089623-A2 | PROCESS FOR PREPARING PITAVASTATIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-07-28 | — | — | WO | claimed |
| CN-101991854-A | Novel blood fat-lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | claimed |
| CN-101991853-A | Statin magnesium-containing blood lipid lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | claimed |
| CN-101961491-A | Novel blood pressure and blood fat reduction composition | BEIJING RUNDEKANG MEDICAL TECH | 2011-02-02 | — | — | CN | claimed |
| CN-101500555-A | Novel formulations comprising fenofibrate and a statin and related methods of treatment | TRANSFORM PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | claimed |
| EP-1922065-A2 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | Transform Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2007019373-A2 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032546-A1 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | ALMBURG, LLC | 2007-02-08 | — | — | US | claimed |
| US-20110294841-A1 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | GUZMAN HECTOR (US) | 2011-12-01 | — | — | US | disclosed |
| CN-101991854-A | Novel blood fat-lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | disclosed |
| CN-101991853-A | Statin magnesium-containing blood lipid lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | disclosed |
| CN-101961491-A | Novel blood pressure and blood fat reduction composition | BEIJING RUNDEKANG MEDICAL TECH | 2011-02-02 | — | — | CN | disclosed |
| US-7642287-B2 | storage stable drug contains pravastatin calcium and an omega-3 oil, wherein the omega-3 oil comprises 46% ethyl ester of eicosapentaenoic acid, 38% ethyl ester of docosahexaenoic acid; anticholesterol agent, antilipemic agent; treating atherosclerosis, hyperlipidemia, cardiovascular disease | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090042979-A1 | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment | TRANSFORM PHARMACEUTICALS INC. (US) | 2009-02-12 | — | — | US | disclosed |
| EP-1786414-A4 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS INC (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007130714-A1 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| CN-1993121-A | Novel statin pharmaceutical compositions and related methods of treatment | TRANSFORM PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1786414-A2 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | Transform Pharmaceuticals, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060034815-A1 | Novel statin pharmaceutical compositions and related methods of treatment | ALMBURG, LLC | 2006-02-16 | — | — | US | disclosed |
| WO-2006017698-A2 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |